ArticleCurrent medical imaging2025
Impact of CT-relevant Skeletal Muscle Parameters on Post-chemotherapy Survival in Patients with Unresectable Pancreatic Ductal Adenocarcinoma
Article in Current medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Pretherapeutic radiological sarcopenia in pancreatic ductal adenocarcinoma: a narrative review.Future science OA · 2026Review
- Postoperative sarcopenia in older patients with hip fractures: incidence and associated risk factors in a retrospective cohort study.Frontiers in medicine · 2026Article
- Opportunistic Screening for Pancreatic Cancer using Computed Tomography Imaging and Radiology Reports.AMIA ... Annual Symposium proceedings. AMIA Symposium · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe study aimed to investigate the association of CT-relevant skeletal muscle parameters, such as sarcopenia and myosteatosis, with survival outcomes in patients receiving chemotherapy for unresectable pancreatic ductal adenocarcinoma (PDAC).
methodsIn this retrospective analysis, patients who began chemotherapy for unresectable PDAC were included. Sarcopenia and myosteatosis were assessed on pretreatment CT at the L3 level by skeletal muscle index and mean muscle attenuation with predefined cutoff values. The Cox proportional hazards model was used to analyze the factors associated with progression-free survival (PFS) and overall survival (OS)
resultsA total of 150 patients were enrolled. Compared to patients without sarcopenia, patients with sarcopenia had significantly worse PFS (p=0.003) and OS (p<0.001). Patients with myosteatosis had significantly worse PFS (p=0.01) and OS (p=0.002) compared to those without myosteatosis. In multivariate analysis, after adjusting for age, sex, tumor size, location, treatment modality, smoking, drinking, underlying diseases, and partial laboratory tests, sarcopenia remained an independent predictor of PFS (p=0.006) and OS (p<0.001). Myosteatosis remained an independent predictor of OS (p=0.008), but not of PFS.
conclusionSarcopenia and myosteatosis are independent prognostic factors for patients with unresectable pancreatic ductal adenocarcinoma after chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.